| P/E (FY) | — | Sales (TTM) | NOK 0 |
| Earnings (TTM) | NOK 57.5M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy. Its programs include TG01, a cancer vaccine targeting driver mutations that is in three clinical trials for multiple myeloma and pancreatic and lung cancer, and circVec, a modular circRNA vector platform. The company has research collaborations with United Immunity for CAR-Macrophage therapy and with Suzhou GenAssist for circVec-enhanced AAV vectors. Formerly Targovax ASA, it is based in Oslo.
| Market Cap | — | Trading Days | 2390 |
| 52W High | 14.46 |
| 52W Low | 0.55 |
| % Off High | −37.97% |
| YTD | 670.62% | 1Y | 1326.07% |
| 3Y | −47.82% | 5Y | −95.05% |
| 10Y | −95.23% | Since incept. (ann.) | −26.03% |
| Ann. Volatility (1Y) | 180.05% | Ann. Volatility (3Y) | 235.52% |
| Sharpe (1Y) | 2.23 | Sharpe (3Y) | 0.59 |
| Max Drawdown (1Y) | −59.37% | Max Drawdown (3Y) | −97.24% |
| Beta (3Y, vs SPY) | −3.64 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.14T | 52.7 |
| JNJ | JOHNSON & JOHNSON | $639.90B | 24.1 |
| ONC | BeOne Medicines Ltd. | $472.90B | 1722.2 |
| ABBV | AbbVie Inc. | $465.20B | 111.6 |
| MRK | Merck & Co., Inc. | $321.97B | 17.9 |
| AMGN | AMGEN INC | $209.21B | 27.2 |
| ABT | ABBOTT LABORATORIES | $188.12B | 29.0 |
| GILD | GILEAD SCIENCES, INC. | $164.79B | 19.6 |
| PFE | PFIZER INC | $143.34B | 18.5 |
| SYK | STRYKER CORP | $135.04B | 41.9 |
| BMY | BRISTOL MYERS SQUIBB CO | $128.85B | 18.2 |
| ISRG | INTUITIVE SURGICAL INC | $124.74B | 44.9 |
